MISSISSAUGA, ON, Nov. 20, 2025 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, the “Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend of US$0.05 per common share, payable in Canadian dollars on December 15, 2025 to shareholders of record at the close of business on November 28th. 2025. This fourth quarter 2025 dividend compares to the third quarter 2025 dividend of $0.05 per common share. This dividend qualifies as an “eligible dividend” for Canadian income tax purposes. The declaration, timing, amount and payment of future dividends remain at the discretion of the Board of Directors.
About BioSyent Inc.
Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable, growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective and have a proven track record of improving patient lives. BioSyent supports the healthcare professionals who treat these patients by promoting its products through its communities, specialties and international business units.
As of the date of this press release, the Company had 11,262,282 shares of common stock outstanding.
For a direct market quote from the TSX Venture Exchange and other financial information about the company, visit www.tmxmoney.com.
For more information contact:
Mr. Rene K. Gerum
President and CEO
BioCent Inc.
E-mail: [email protected]
Phone: 905-206-0013
Internet: www.biosyent.com
This press release may contain forward-looking information or statements. The contents herein represent our judgment as of the date hereof and are subject to risks and uncertainties that could cause actual results or performance to differ materially from the forward-looking information or statements. Potential risks may include, but are not limited to, risks associated with clinical trials, product development, future revenues, operations, profitability and regulatory approvals.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
